Introduction
Thrombus is traditionally defined as the product of blood coagulation in a flowing bloodstream; its principal component is aggregated fibrin, with varying proportions of platelets, leucocytes and erythrocytes ( Figure 1 ). Thrombolysis is, strictly, the therapeutic dissolution of thrombus by any means; it is frequently used synonymously with fibrinolysis, in which fibrin strands are broken down by the enzymatic cleavage of fibrin. All current fibrinolytic therapy involves the activation of plasminogen, a serine protease proenzyme which circulates in plasma and also binds selectively to lysine residues of fibrin.' Fibrinolysis by plasminogen activation is effective partly because of this affinity of plasminogen for fibrin, and partly because the process becomes autocatalytic, with further activation of plasminogen by plasmin ( Figure 2 ). The major unwanted side effect of fibrinolysis is bleeding. Conceptually, one can distinguish between bleeding which is due to disruption of a haemostatic fibrin plug (type 1 bleeding) and bleeding which is due to some disruption of systemic haemostasis as a side effect of fribinolysis (type 2 bleeding). It was hoped that agents which selectively activated fibrin-bound as opposed to circulating plasminogen would be associated with less depletion of circulating fibrinogen, fewer circulating fibrinogen degradation products, and © Edward Arnold 1994 hence less bleeding. These hopes have been only partly fulfilled. Clinical thrombolysis frequently involves a 'trade off between speed and efficacy on one hand and safety on the other, and the balance frequently depends critically on the precise clinical circumstances. Current clinical strategies, unanswered questions and future strategies are discussed below.
Coronary thrombolysis

Fibrinolysis
By far the largest clinical experience with thrombolysis has been in the context of acute coronary thrombosis. A number of reviews have detailed the history of this experience.? Salient landmarks include the concept of highdose, short-duration thrombolysis.> the interaction between fibrinolytic therapy and aspirin," and the extensive use of large-scale, mortality endpoint clinical trials.> There is now good evidence that intravenous fibrinolytic therapy (plus aspirin) improves survival in all types of infarct, in patients of either gender, and irrespective of patient age ( Table 1 ). The improvement in outcome is maximized by starting treatment as soon as possible, but fibrinolytic therapy may be worthwhile up to 12 hours after symptom onset.v Table 1 Absolute benefits of thrombolytic therapy thrombus contains and releasesplatelet-derived products including platelet activating factor and thromboxaneA2, 18(3) 35 ( Clinically available thrombolytic agents include streptokinase, anistreplase, urokinase, alteplase and saruplase ( Table 2 ). Mortality endpo int comparisons between different agents need to involve very large numbers of patients if they are to have adequate power, and the number of regimens that can be compared is limited. ISIS-3 showed no mortality difference between streptokinase, anistreplase and duteplase (double-chain rt-PA (recombinant tissue plasminogen activator) , probably essentially equivalent to alteplasej .? and the GISSI-2lIntemational Study Group trials 8 • 9 showed no difference between streptokinase and alteplase. Neither of these trials used tepA in conjunction with intravenous heparin. GUSTO , which used a 'front-loaded' alteplase regimen combined with adjusted intravenous heparin, found the combination significantly more effective than streptokinase with either intravenous or subcutaneous heparin, or a combination of 'nonfront-loaded' alteplase with streptokinase.t? The survival benefit with front-loaded alteplase compared to streptokinase was an absolute mortality difference of about 1% at 30 days. In a parallel angiographic substudy, the accelerated alteplase regimen was associated with better coronary patency at 60 and 90 minutes , though the other regimens subsequently 'caught up' .!!
The most dangerous form of fibrinolysisassociated haemorrhage is intracranial bleeding . A recent meta-analysis's has indicated that the principal risk factors for this are age> 65 years , The clinical choice of the most appropriate fibrinolytic agent will take account of cost and ease of use as well as efficacy and safety. Because of the large cost differential between, say, alteplase and streptokinase the debate on choice of fibrinolytic agent remains open.
Coronary angioplasty
The main 'competitor' to intravenous fibrinolytic therapy is primary coronary angioplasty: in effect, a form of mechanical thrombolysis. Trials suggest this is of at least equivalent efficacy to fibrinolytic therapy, with a lower risk of major cerebral haemorrhage. 13 .14 Again, cost and availability are potential limiting factors.
An alternative approach to increasing the dose of fibrinolytic agent, with its attendant risk of cerebral haemorrhage, is to decrease the dose of fibrinolytic, but to combine it with an Table2 Clinically available thrombolytic agents Editorial 279 effective anticoagulant. The development of new generations of antithrombins (for example, recombinant hirudin, hirulog, argatroban) agents which in~ibi~the platelet IIb/IIIa recepto; and platelet activaung factor antagonists provide considerable scope for this; however, most current trials seem to be aimed at demonstrating increased efficacy, rather than better safety, of new fibrinolytic regimens. The demonstration in the GUSTO study that angiographic patency rates did after all relate to better clinical outcome will almost certainly encourage further 'surrogate endpoint' studies as well as the very large trials necessary if mortality is the only endpoint.
Other indications for thrombolytic therapy
Thrombolytic therapy has been used, or at least tried, for almost every pathological entity involving thrombosis ( Table 3 ). For none of these, however, is there such convincing evidence of therapeutic benefit. In deep vein thrombosis fibrinolysis improves angiographic appearances, Table 3 Noncoronary usesof thrombolytic therapy but a significant effect on long-term outcome is still debated. In acute pulmonary embolism there is also convincing evidence of haemodynamic and angiogaphic improvement,> but an overall effect on mortality has yet to be demonstrated. Because of the extremely adverse haemodynamic effects of a large thromboembolus wedged in the main pulmonary artery or right ventricular outflow tract, there has been increased interest here too in mechanical thrombolysis, either using ordinary cardiac catheters to break up thrombus, or more sophisticated devices to macerate or remove it. In peripheral arterial thrombosis (or thromboembolism) there is also a trend towards using fibrinolytic agents by local applicaticn's and to combining them with surgical embolectomy or angioplasty. Fibrinolytic therapy has been used successfully to free thrombosed prosthetic heart valves, but reported series are small, and the possibility of negative publication bias may distort results. Undoubtedly the major remaining challenge for thrombolytic therapy is in the treatment of thrombotic stroke. There are two main obstacles to this: first, the differential diagnosis between thrombotic and haemorrhagic stroke, which is often not clinically obvious; second, the risk of converting a small and self-limited cerebral infarct into a large and spreading cerebral haemorrhage. The problem of diagnosis will eventually be overcome by the more widespread availability of computed tomographic scanning. The problem of secondary haemorrhage may be averted by confining treatment to patients in whom a diagnosis is made early, and in whom the occluded cerebral vessel can be recanalized before hypoxia-induced and time-related processes have so weakened the vessel wall that reperfusion results in haemorrhage.
Future thrombolytic prospects
Some potential developments have already been referred to, including the possible use of rational combinations of fibrinolytic and antithrombotic agents to reduce the dose of fibrinolytic without compromising efficacy. Others, such as the potential scope for using fibrinolytics as powerful but localized anticoagulants, are outside the scope of this review. It is becoming clearer that optimizing the pharmacokinetics of fibrinolytic agents for specific tasks may be important both for their efficacy, and even more for their ease of use; however, the expense of large-scale trials and the necessity of recouping it by a premium on drug cost is a potential disincentive to further study.F 'Mixed mode' thrombolysis, in which the efficacy of a fibrinolytic drug is enhanced by combining it with a mechanical or phyiscal process, remains attractive despite the lack of success, never adequately explained, of angioplasty as an adjunct to fibrinolytic therapy in coronary thrombosis.tf At a biochemical level, attempts to produce 'designer' fibrinolytics by genetic engineering of, for example, t-PA have produced substances of great theoretical interest, but as yet little commercial potential.l~22 The potential of a really thrombus-selective fibrinolytic, with selectivity perhaps one or two orders of magnitude greater than presently available, remains to be evaluated: should it be feasible to produce such an agent? We also need to know more about reperfusion associated haemorrhage in the brain: to what extent is this simply related to reperfusion after hypoxia, or to the effects of plasmin on vessel wall integrity? If the latter, would there be scope for a fibrinolytic which bypassed plasminogen and acted directly on fibrin? Resolution of these and other issues will result in wider adoption of this important mode of vascular therapy.
